Defective X-gating caused by de novo gain-of-function mutations in KCNK3 underlies a developmental disorder with sleep apnea

Sleep apnea is a common disorder that represents a global public health burden. KCNK3 encodes TASK-1, a K+ channel implicated in the control of breathing, but its reported link with sleep apnea remains poorly understood. Here we describe a novel developmental disorder with sleep apnea caused by rare de novo gain-of-function mutations in KCNK3. The mutations cluster around the X-gate, a gating motif which controls channel opening, and produce overactive channels that no longer respond to inhibition by G-protein coupled receptor pathways but which can be inhibited by several clinically relevant drugs. These findings demonstrate a clear role for TASK-1 in sleep apnea and identify possible therapeutic strategies.


Introduction
Sleep apnea is thought to affect up to 1 billion people worldwide and is characterized by abnormal, interrupted breathing during sleep 1,2 . The poor quality of sleep that arises results in huge economic and societal impact, a decreased quality of life, and increases the risk of comorbidities such as cardiovascular disease, diabetes and depression, as well as the risk of motor vehicle accidents 3 . Sleep apnea is therefore a major public health burden and there is a large unmet clinical need for more effective treatments 4

.
However, it is also a complex disorder and the mechanisms involved are often unclear.
Increasing evidence suggests that instability of ventilatory control is involved in the pathogenesis of both central and obstructive sleep apnea, the two principal forms of the disorder 1 . Peripheral and central chemoreceptors which detect O2/CO2 levels also play a critical role, though their molecular identity and the neuronal networks involved remain poorly defined 5 . Two-Pore Domain K + channels (K2P) are a structurally distinct subset of K + channels where each gene encodes a subunit with two pore-forming domains that co-assemble as a 'dimer of dimers' to create a single pseudotetrameric K + selective channel across the membrane 6,7 . K2P channels underlie the background K + currents that control the membrane potential in many different cell types. Originally described as 'leak' channels, their activity is now known to be regulated by diverse stimuli, including many G-protein where dysfunctional regulation of this pathway gives rise to an increased frequency of spontaneous apneas 11 .
KCNK3 encodes the TASK-1 K2P channel and is expressed in a variety of neuronal populations throughout the central nervous system, including many chemosensitive regions involved in the control of ventilation as well in hypoglossal and spinal cord motor neurons [12][13][14] . In peripheral tissues, TASK-1 is also found in the carotid bodies, lung, heart, and pulmonary arterial smooth muscle [15][16][17] . Its expression throughout these tissues has therefore implicated TASK-1 in the control of breathing and also in sleep apnea 12,[18][19][20][21][22] . Furthermore, an X-ray crystal structure of the TASK-1 channel has recently been reported in complex with a compound class of TASK-1 inhibitors currently in clinical trials for the treatment of sleep apnea 23 . This structure also revealed several unique features of TASK-1, including a lower 'X-gate', a structural motif which controls opening and closing of the channel pore 23 .
However, a clear mechanistic link between TASK-1 and sleep apnea remains unproven and is further complicated by the propensity of TASK-1 subunits to co-assemble with related TASK-3 (KCNK9) subunits to form novel heteromeric TASK-1/TASK-3 channels in cells where both genes are coexpressed 24,25 . Moreover, heterozygous loss-offunction variants in KCNK3 are associated with a different disorder, pulmonary arterial hypertension (PAH), an adult-onset, progressive and often fatal disease characterized by increased pulmonary arterial pressure in the absence of the common causes of pulmonary hypertension 26 ; in addition loss-of-function mutations in the TASK-3 channel (KCNK9) are associated with a neurodevelopmental disorder, Birk Barel syndrome 27 .
In this study we describe nine probands with de novo missense mutations in KCNK3 who exhibit global developmental delay, hypotonia, and central/obstructive sleep apnea . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint with a range of structural malformations. The mutations all cluster near the recently identified lower X-gate of the TASK-1 channel and result in a novel gain-of-function phenotype that correlates with the severity of their disorder. These results have important implications for the treatment of these probands and other individuals with sleep apnea, as well as for our understanding of the role that TASK-1 channels play in cellular function.

Recurrent missense mutations in KCNK3 cause developmental delay with sleep
apnea A recent analysis of 31,058 parent-offspring trios with severe developmental disorders identified 28 novel disease-causing genes with a high burden of de novo mutations, including one caused by recurrent missense variants in KCNK3 (ENST00000302909; NM_002246) 28 . Through parent-offspring exome sequencing performed across four different diagnostic laboratories and research studies, we have now identified a total of nine probands, each heterozygous for one of six de novo missense variants in KCNK3 (Methods and Table 1). These novel mutations were found to cluster in two regions of the protein (ENSP00000306275.3; NP_002237): variants in KCNK3 are associated with a completely different adult-onset disorder 26 , we hypothesized that DDSA may be caused by a different mechanism. 1 We therefore examined the functional activity of all these DDSA mutations by heterologous expression of either wild-type (WT) or mutant channels in Xenopus oocytes. Two-Electrode Voltage Clamp (TEVC) recordings revealed whole-cell K + currents markedly larger than WT TASK-1. Only one variant, L239P in the M4 helix, produced whole-cell currents similar in size to WT TASK-1 (Fig. 1c,d and Supplementary Fig. 2a).

DDSA mutations produce a gain-of-function phenotype in TASK-
The mutant currents all exhibited reversal potentials around -80 mV in low external [K + ] consistent with K + selective channels (Fig. 1d). The L122V mutation produced the largest increase in current compared to WT consistent with the activatory effect of mutations at the structurally equivalent position in many other K2P channels 34 . Overall, the mutations located in M2 produced the largest increase in current compared to WT TASK-1 (3.2-6.2-fold), whereas the two M4 mutations were either similar in size to WT (i.e. L239P), or only ~2.8-fold (i.e. L241F; Fig. 1d).

Gain-of-function in 'heterozygous' TASK-1 and heteromeric TASK-1/TASK-3
channels K2P channels are dimeric and the results described above were all obtained in homomeric channels where both subunits contain the mutation. However, the DDSA probands are heterozygous for a single mutation, meaning a mixture of channels can be created from coassembly of WT and mutant subunits (25% WT, 50% 'heterozygous' and 25% 'homomeric' mutant). Therefore to better replicate this heterozygous genotype, we co-injected oocytes with WT TASK-1 mRNA plus an equal amount of either WT or mutant mRNA in a 1:1 ratio. In all cases, the resulting currents were at least 80% the size of currents formed by homomeric mutant channels (Fig. 1e). An increase in current . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint was also observed for the most common DDSA variant (N133S) in a 'pure' heteromeric channel formed from a covalently linked WT/mutant tandem dimer which constrains channel stoichiometry (Supplementary Fig. 2b).
TASK-1 can also coassemble with TASK-3 subunits to form novel heteromeric channels in vivo 24,25 . We therefore co-injected oocytes with WT TASK-3 mRNA plus an equal amount of either WT or mutant TASK-1 mRNA. In this case, all the mutants, including L239P, produced larger heteromeric TASK-1/TASK-3 currents than when WT TASK-1 was used (Fig. 1f). This demonstrates that all these DDSA mutations produce a gain-offunction in either heterozygous TASK-1 and/or heteromeric TASK-1/TASK-3 channels.
This effect is clearly different to the loss-of-function observed for KCNK3 mutations associated with PAH 26 , including the recently characterized missense variant, L214R 35 ; Supplementary Fig. 2c,d). In further support of our findings, we did not observe any functional effect of a control variant (H141Q) (Supplementary Fig. 2e). This variant, which is also located in the M2 helix, is present in 194 individuals in the gnomAD database 36 and annotated as likely benign in ClinVar 37 .

DDSA mutations increase channel open probability
The whole-cell currents (I) described above are a product of the number of channels in the membrane (N) and their individual open probability (Po). However, trafficking of mutant proteins to the membrane is normally impaired by mutations and rarely increased; also membrane trafficking in an oocyte does not necessarily reflect what happens in more complex native cells, especially neurons 17, 38 . We therefore measured the properties of single TASK-1 channels for the N133S variant in M2, and for L239P in M4 (Fig. 2a-d). Similar to previous reports, we found the Po of WT TASK-1 was extremely low (Po ~ 0.02) with a single channel conductance of ~13 pS 39 . However, homomeric N133S mutant channels . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; exhibited an increased Po ~10-fold greater than WT TASK-1 ( Fig. 2c) with an unchanged single channel conductance (Fig. 2d), an effect consistent with previous reports of other mutations at this position in both TASK-3 and TASK-1 23,40 . We also observed a similar effect for the L239P mutation with a 10-fold increase in estimated Po, though its "blurry" open channel histogram indicates that its effects on single channel properties are more complex and warrant further investigation (Fig. 2b).

DDSA mutations destabilize the closed X-gate in TASK-1 Destabilization of the
interactions which hold the channel closed will increase the frequency of channel openings (i.e. increase Po) and is consistent with the location of these DDSA mutations near the X-gate. In particular, the recurrent mutation N133S on M2 involves changes to an amino acid that participates in a hydrogen bond predicted to stabilize the X-gate when closed 23,40 . To investigate this further, we examined multiple substitutions at this position, all of which resulted in a gain-of-function indicating the critical role of this hydrogen bond (Supplementary Fig. S3a,b).
In addition, we performed molecular dynamics simulations on WT and both N133S and L239P mutant channel structures. These structures were embedded within a lipid bilayer and multiple repeats of equilibrium simulations each run for 500 ns. The results show the lower X-gate remained firmly closed in all simulations of the WT channel, but began to open in simulations of the N133S and L239P mutant channels (Fig. 2e).
Interestingly, we previously proposed a twist and straightening was required to open the X-gate 23 and similar movements were observed in simulations of the N133S mutant channel (Supplementary Fig. S3c).

DDSA mutations result in defective X-gating and dysfunctional GPCR-mediated
inhibition TASK channels have been shown be inhibited in vivo by multiple hormones . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint and transmitters including ATP, thyrotropin-releasing hormone, serotonin, glutamate, catecholamines and acetylcholine that all act through G protein-coupled receptors (GPCR) signaling via G proteins of the Gαq/11 subclass (Gαq) 9,13,17,32 . Furthermore, mutation of residues in M2 and in the X-gate itself have been shown to impair this process 32,33 . We therefore examined the ability of these DDSA mutations to affect such regulation.
To reflect the heterozygous probands, we co-expressed equal amounts of WT and mutant TASK-1 mRNAs and measured their inhibition by either carbachol via endogenous muscarinic receptors, or by ATP via a coexpressed P2Y receptor as reported previously 41,42 . However, unlike WT TASK-1, we found that GPCR-mediated inhibition by either approach was markedly impaired in all 'heterozygous' DDSA mutant co-expressions ( Fig. 3a-d). This effect was similar to that observed when these mutations were expressed as homomeric channels (Supplementary Fig. S4a). By contrast, GPCR-regulation of the 'benign' H141Q variant appeared unaffected ( Supplementary Fig. S4b).
The impaired GPCR-mediated inhibition of these DDSA mutations therefore amplifies their gain-of-function effect such that, after GPCR activation, their remaining currents were all greater than WT TASK-1. Importantly, this effect was notable even for the WT/L239P channel, which was initially similar in size to WT TASK-1, but the currents were ~2-fold larger than WT after receptor stimulation (Fig. 3b,d). This GPCRinsensitivity also affected heteromeric TASK-1/TASK-3 channels that contained mutant TASK-1 subunits (Supplementary Fig. S4c).

Druggability of DDSA mutations
Unlike many other K2P channels which exhibit relatively poor pharmacology 31 , TASK-1 can be inhibited by a range of potent and highly . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. selective small molecules, including a number of clinically relevant drugs such as doxapram, carvedilol and bupivacaine 43 . The most potent inhibitor of TASK-1 known to date is BAY1000493 which binds deep within the pore of the channel 23 , and is a close analog of another TASK-1 inhibitor recently used in a clinical trial for the treatment of obstructive sleep apnea (the 'KOALA' trial, NCT04236440 currently being progressed into a larger Phase 2 study).
Using our ability to record TASK-1 activity in giant excised membrane patches, we were able to accurately measure the inhibition of WT TASK-1 by BAY1000493 (Fig 4a,b); this produced half-maximal inhibition at a concentration of ~1 nM (IC50= 970 pM ± 250 pM, n=10) making it the most potent TASK-1 inhibitor known to date. 1 nM BAY100493 was slightly less effective on TASK-1 N133S and L241F mutant channels (Fig. 4a), but full dose-response measurements revealed that all five DDSA mutants still exhibited sensitivity to this drug within the low nanomolar range with IC50 values ranging from 5 -23 nM (Fig. 4b). We also examined a range of other known high affinity inhibitors of WT TASK-1 on the N133S mutation; these included PK-THPP, A1899, A293 and Tetrapentylammonium (TPA) 43 , all of which we found to have similar IC50 values compared to WT TASK-1 (Fig. 4c). This mutation also did not affect the reported sensitivity of TASK-1 to inhibition by several drugs already in clinical use including bupivacaine, carvedilol, and the respiratory stimulant doxapram (Fig 4c). This result is in marked contrast to the reported effect of other gain-of-function mutations, e.g. the L244A and M247A mutations engineered into the X-gate of TASK-1 which also both increases channel activity, but which markedly reduce BAY1000493 sensitivity 23 . The druggability of these DDSA gain-of-function mutations therefore highlights potential therapeutic strategies for these probands.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Mechanism of GPCR-mediated inhibition
The molecular mechanism of Gαqmediated inhibition is unclear and reported to involve non-canonical effects of pathway activation 41,44 . Normally, Gαq activates phospholipase C (PLC) which hydrolyses phosphatidylinositol (4,5) bisphosphate (PIP2), a lipid which supports the activity of many K2P channels, and so PIP2 degradation usually reduces channel activity 9,41,45 .
However, it appears that it is the concomitant increase in diacylglycerol (DAG) upon PIP2 hydrolysis which is primarily responsible for TASK channel inhibition rather than the loss of PIP2 41,[44][45][46] . DAG has been shown to directly inhibit TASK-3 channel activity 44 and we now show that the DAG analogue, DiC8 also directly inhibits TASK-1 with nanomolar efficacy in excised patches. However, this inhibitory effect is severely impaired by the recurrent DDSA mutation, N133S (Fig. 4d).
PLC activation can also affect the levels of many other signaling lipids, including the endocannabinoid, anandamide (AEA) which directly inhibits TASK-1 47 , and we found that the N133S mutation also impairs the inhibitory effect of AEA (Fig. 4e). Extracellular pH is also known to regulate TASK channel activity 7 . We therefore examined the response of the N133S mutation to changes in extracellular pH and found that although its activation by alkalinization was blunted, its inhibition by extracellular H + remained mostly intact (Fig. 4f).

Discussion
In this study, we describe a new monogenic channelopathy, Developmental Delay with Sleep Apnea (DDSA), resulting from heterozygous de novo gain-of-function mutations in KCNK3. These mutations result in defective X-gating of TASK-1 and increased K + currents through these channels. Although DDSA is rare, our results also now highlight . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint the important link between TASK-1 channels and sleep apnea, and identify therapeutic opportunities for both DDSA patients and those who suffer from sleep apnea.
TASK-1 channels (including heteromeric TASK-1/TASK-3) have long been regarded as attractive targets for the treatment of sleep apnea 48 . However, even though drugs that target TASK-1 are currently being progressed into Phase 2 clinical trials for treatment of sleep apnea, a clear link with this disorder has not been established and has even been questioned 49 . Furthermore, until now, the only known genetic mutations in TASK-1 were associated with a completely different, hypertensive phenotype 26 .
Our results therefore provide the first direct evidence of a link between KCNK3 and sleep apnea due to a new class of de novo gain-of-function mutations that have very different effects on cellular electrical activity compared to the loss-of-function mutations associated with PAH. This causal link is not only consistent with expression of TASK-1 in many of the chemosensitive cell types and tissues involved in regulation of breathing, but also with the fact that current clinical trials for sleep apnea aim to suppress TASK-1 K + channel activity.
The DDSA probands identified in this study all have a developmental disorder that includes sleep apnea as well as a number of other cognitive and musculoskeletal phenotypes (see Table 1). It is well known that inappropriate spatiotemporal expression of an ion channel can affect the development of many cell types, especially neurons 50 and studies in developing mouse embryos have shown that KCNK3 is expressed at an early stage especially in the developing CNS 14 . It is also important to note that the effect of these DDSA mutants on electrical activity will be very different to the loss-of function PAH mutations in TASK-1. The phenotype in these probands could therefore arise via several possible mechanisms: a general increase in homomeric TASK-1 activity, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint increased heteromeric TASK-1/TASK-3 activity, and/or the resistance of these channels to inhibition by Gαq-coupled signaling pathways (see Fig. 5). However, the relative contribution of these different molecular mechanisms will be difficult to dissect.
Despite the many phenotypic features shared by the probands, the two with mutations in the M4 helix were much less severely affected than the probands with mutations in the M2 helix, including only mild developmental delay and no structural abnormalities.
Interestingly, these M4 mutations (L239P and L241F) each produced the smallest overall increase in whole-cell currents. This genotype-phenotype correlation may therefore provide insight into the mechanisms underlying the DDSA phenotypes, but further studies are required to confirm this. Strikingly, central and/or obstructive sleep apnea was experienced by all (living) probands, and the general gain-of-function in TASK-1 is common to all these variants. We also note that, despite the reported overexpression of KCNK3 in atrial fibrillation 51 , none of these DDSA probands exhibited any obvious cardiac phenotype.
The functional properties of these mutations provides further insight into the molecular mechanism of TASK-1 gating; in particular, how the X-gate opens and how this is regulated by Gαq-coupled pathways. In the structure of TASK-1, the channel pore is occluded by the lower X-gate 23 . The six residues in M4 that form this constriction were previously identified as important for channel regulation by volatile anesthetics and by several Gαq-coupled pathways, though the mechanisms involved were unclear 32 . Our results show that the DDSA mutations all cluster near the X-gate in its closed conformation and are likely to disrupt stability of the closed X-gate. In particular, the recurrent N133S variant destabilizes a critical H-bond and promotes channel opening.
Likewise, the inhibitory effect of DAG on TASK-1 channels suggest that it favors stability . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint of the closed state. The fact that all DDSA mutations produce similar effects in both homomeric and 'heterozygous' channels also suggests that disruption of the X-gate within a single subunit is sufficient to open the channel.
The increased whole-cell currents generated by these DDSA mutants result primarily from an increase in channel Po rather than an increased number of channels at the cell surface, and in some cases the mutants may even decrease surface expression; e.g.
the L239P mutant has a 10-fold greater Po, but has similar whole-cell currents to WT TASK-1, an effect that can only result from fewer channels in the membrane. However, Gαq-mediated inhibition of the L239P mutant channel is also completely abolished and so the remaining currents become ~2-fold larger than WT TASK-1 and therefore represent a gain-of-function effect.
Fortunately, despite their activatory effects, these mutants all retain their sensitivity to a number of small molecule inhibitors, some of which are already in clinical use and/or ongoing clinical trials. This offers a realistic prospect for therapeutic intervention in DDSA probands that may improve their quality of life. It remains to be determined precisely how TASK-1 dysfunction produces the phenotype observed in DDSA, in particular sleep apnea. However, our findings markedly strengthen the proposed use of TASK-1 inhibitors to treat sleep apnea and provide important new insights into a sleep disorder that severely impacts many millions of lives.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Genetics:
Four probands were identified through the UK Deciphering Developmental Disorders (DDD) Study, which has been described previously 52,53 . Briefly, probands with severe, undiagnosed developmental disordered and their parents were recruited and phenotyped by referring clinical geneticists in 24 regional genetics services across the National Health Services in the UK and Ireland. Saliva and/or blood-extracted DNA samples were analysed at the Wellcome Sanger Institute using massively parallel whole . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Next Generation sequencing instrument, using HapMap Sample NA12878 as an internal control. Paired-end 101 base-pair reads were aligned to a modified human reference genome (GRCh37/hg19) using Novoalign. Sequencing quality was evaluated . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint using FastQC. All germline variants were jointly called through GATK Haplotype Caller and GenotypeGVCF and each variant was annotated using the BioR Toolkit. Using a custom-developed analysis tool, data were filtered and analyzed to identify clinically relevant sequence variants. Variants of interest were confirmed by automated Sanger sequencing. For all studies, candidate de novo mutations in KCNK3 were visually inspected using the Integrative Genomics Viewer (IGV) 60 . Likely diagnoses were communicated to referring clinical teams for diagnostic validation (including confirmation by Sanger sequencing where appropriate) and discussion with the family.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint Electrophysiology. The wild-type human TASK-1 gene (KCNK3) was subcloned into a plasmid vector (pFAW) suitable for in vitro transcription and expression in Xenopus laevis oocytes 61 . Mutations were introduced by site-directed mutagenesis and confirmed by sequencing. Unless otherwise stated, a volume of ~18 nl of mRNA was injected oocytes at a concentration of 110 ng/μl for either wild-type or mutants (i.e. 2 ng of RNA per oocyte). Two-electrode voltage clamp recordings were performed as previously described 61 . Briefly, after injection of mRNA, oocytes were incubated for 20-24 h at 17.5°C and measured in ND96 buffer at pH 7.4 (96 mM NaCl, 2 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES). Unless otherwise stated, currents were recorded using a 400 ms voltage step protocol from a holding potential of -80 mV delivered in 10 mV increments between -120 mV and +50 mV and 800 ms ramp protocols from -120 to +50 mV. All recorded traces were analyzed using Clampfit (Axon Instruments), and graphs were plotted using Origin2019b (OriginLab Corporation). Unless otherwise described, all results shown are reported as mean ± standard deviation and obtained with oocytes from at least 3 independent batches. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint glycerol (DiC8) were purchased from Sigma-Aldrich. PK-THPP, A1899, Carvedilol and Anandamide (AEA) were purchased from Tocris Bioscience. TASK-1 K2P specific inhibitor BAY1000493 was synthesized by Bayer AG as previously described 23  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint the minimum pore radius at lower X-gate during three independent repeats of molecular dynamics simulations of the WT TASK-1 structure compared to either the N133S mutant structure, and the L239P mutant.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021. ;   x2 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted August 9, 2021.   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.05.21261490 doi: medRxiv preprint